Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$4.2 million.

  • BioLineRx's Change in Acquisitions & Divestments rose 2731.83% to -$4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.0 million, marking a year-over-year increase of 5166.68%. This contributed to the annual value of -$26.4 million for FY2024, which is 4462.89% up from last year.
  • Latest data reveals that BioLineRx reported Change in Acquisitions & Divestments of -$4.2 million as of Q3 2025, which was up 2731.83% from -$12.5 million recorded in Q2 2025.
  • BioLineRx's Change in Acquisitions & Divestments' 5-year high stood at $16.7 million during Q1 2024, with a 5-year trough of -$37.3 million in Q2 2024.
  • Over the past 3 years, BioLineRx's median Change in Acquisitions & Divestments value was -$6.8 million (recorded in 2023), while the average stood at -$10.3 million.
  • Over the last 5 years, BioLineRx's Change in Acquisitions & Divestments had its largest YoY gain of 40398.18% in 2024, and its largest YoY loss of 726719.37% in 2024.
  • BioLineRx's Change in Acquisitions & Divestments (Quarter) stood at -$33.7 million in 2023, then surged by 82.82% to -$5.8 million in 2024, then rose by 27.32% to -$4.2 million in 2025.
  • Its Change in Acquisitions & Divestments was -$4.2 million in Q3 2025, compared to -$12.5 million in Q2 2025 and -$12.3 million in Q1 2025.